Clinical condition |
Most frequently used treatments |
Other available treatments |
Renal pruritusa |
– Emollients ± menthol 0.25% + camphor 0.25% tid – Optimization of RRT and increasing dialysis dose – Activated charcoal 6 g/d – UVB phototherapy – Topical 0.03% tacrolimus ointment bid – Capsaicin cream 0.025%-0.075% up to tid – Oral antihistamines (eg, hydroxyzine 10-25 mg PO qid as needed or diphenhydramine 25 mg PO qid as needed) – Gabapentin (eg, 100-300 mg after hemodialysis or at bedtime) – Pregabalin (eg, 25-50 mg after dialysis or at bedtime) |
– Sertraline 25-200 mg/d – Thalidomide 100 mg at night – Naltrexone 50 mg/d – Cholestyramine 5 g bid – Montelukast 10 mg/d PO – Ondansetron 4-8 mg PO, once daily to bid – Doxepin 25-50 mg at bedtime – Nalfurafineb 5 microg IV after hemodialysis |
Cholestasis |
– Bile duct stenting – Bile acid sequestrants (eg, cholestyramine [4-16 g/d PO; advise patients to take other drugs ≥1 h before or 4-6 h after each cholestyramine dose] or colesevelam (1875 mg bid in case of intolerable adverse effects secondary to cholestyramine) – UDCA 12-15 mg/kg/d PO in 3 divided doses – Rifampin 150-300 PO bid (monitor LFTs regularly due to risk of hepatitis) – SSRIs (eg, sertraline 50-100 mg/d, paroxetine 5-20 mg/d, fluvoxamine 25-100 mg/d) – Mu-opioid receptor antagonists (eg, naltrexone 12.5-50 mg/d PO or naloxone 0.4 mg IV bolus followed by 0.2 microg/kg/min for 24 h) |
– UVB phototherapy – Transdermal buprenorphine 5-10 microg/h (if patient has received another opioid for pain, try switching to buprenorphine using dose conversion for opioid rotation; see Pain Management: Basic Principles) – Androgens – Tropisetronb – Propofol
|
Polycythemia vera |
– Emollients – Low-dose aspirin – Phototherapy (eg, narrow-band UVB or PUVA) |
– SSRIs (eg, sertraline 25-100 mg/d) – Paroxetine 5-20 mg/d, fluvoxamine 25-100 mg/d, or fluoxetine – Sedative H1 antihistamines (hydroxyzine) – H2 antihistamines (cimetidine) – Hydroxyurea or interferon alpha (if cytoreduction is indicated) – JAK inhibitors (ruxolitinib) – Thalidomide |
Hodgkin lymphoma |
– Topical and systemic glucocorticoids – H1 antihistamines (eg, cetirizine up to 20 mg bid) |
– Cimetidine 800 mg/d – Mirtazapine 7.5-30 mg at bedtime – Sertraline 25-100 mg/d – Carbamazepine 200 mg bid |
Paraneoplastic pruritus in patients with solid tumors |
Paroxetine 5-20 mg/d, sertraline 25-100 mg/d, or fluvoxamine 25-100 mg/d |
Mirtazapine 7.5-30 mg at bedtime |
Epidural or subarachnoid opioids |
Intrathecal bupivacaine, prophylactic ondansetron 4 mg IV, gabapentin, mirtazapine |
NSAIDs, antihistamines, ondansetron 4-8 mg IV, nalbuphine hydrochloride, butorphanol, naloxone or naltrexone, propofol, promethazine |
Systemic morphine or other opioids |
Emollients, lowering ambient temperature, benzodiazepines, first-generation H1-receptor antagonists |
Switching to another opioid (especially in the case of morphine) if pruritus does not resolve within a few days and is very uncomfortable; ondansetron, paroxetine |
Neuropathic pruritus |
– Topical capsaicin – TCAs (eg, amitriptyline 10-50 mg PO at bedtime) – Antiepileptic drugs (eg, gabapentin 300-900 mg/d divided in 2-3 doses and pregabalin 75-150 mg/d PO) – Mirtazapine 15-30 mg PO at bedtime |
NSAIDs |
Other causes or idiopathic pruritus |
Sertraline or paroxetine |
Mirtazapine, gabapentin, aprepitant |
a Exclude hyperparathyroidism. b Not available in Canada. |
||
bid, 2 times a day; IV, intravenous administration; JAK, Janus kinase; LFT, liver function test; NSAID, nonsteroidal anti-inflammatory drug; PO, oral administration; PUVA, psoralen and ultraviolet A; qid, 4 times a day; RRT, renal replacement therapy; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; tid, 3 times a day; UDCA, ursodeoxycholic acid; UVB, ultraviolet B. |